Sarcopenia Prevention With a Targeted Exercise and Protein Supplementation Program

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

801 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-25

Study Completion Date

2025-03-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Physical inactivity and protein malnutrition have been implicated to be key and modifiable causes of enhanced muscle mass loss among seniors. However, the individual benefit, as well as the additive or possibly interactive benefit of exercise and Protein supplementation on fall prevention has yet to be confirmed in a large clinical trial. This study aims to test the individual and combined effect and cost-effectiveness of a simple home exercise program and / or protein supplementation on the risk of falling in seniors at high risk of progressive muscle mass loss and sarcopenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improvement of Sarcopenia in Patients Following Two Different Diets

NCT03405727

Sarcopenia

WITHDRAWN NA

Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia

NCT02374268

Sarcopenia

COMPLETED NA

Effect of Low Intensity Exercise and Protein Intake on Skeletal Muscle Protein Synthesis in Elderly

NCT01640145

Skeletal Muscle Protein Synthesis in Elderly Protein Kinetics Sarcopenia

COMPLETED NA

A Protein Supplementation and Exercise Strategy to Promote Muscle Protein Anabolism in Frail Elderly People

NCT01110369

Sarcopenia

COMPLETED NA

Improvement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise

NCT07049731

Sarcopenia

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The number of seniors age 75 and older is predicted to double by 2030, as is the number of seniors with mobility disability, physical frailty and resulting consequences, such as falls and loss of autonomy. This causes an enormous challenge to the individual, to medical care, and the society as a whole. A condition that is considered central to the development of physical frailty and its consequences is sarcopenia, the loss of muscle mass and strength. To date sarcopenia is underdiagnosed in clinical care and effective treatments for sarcopenia are missing.

This study aims to test the individual and combined effect and cost-effectiveness of a simple home exercise program and / or protein supplementation on the risk of falling in seniors at high risk of progressive muscle mass loss and sarcopenia.

The STRONG trial will be a 2x2 factorial design multi-centre double-blind randomized controlled clinical trial among 800 senior men and women; study duration is 12 months. The primary endpoint is the rate of falling. Key secondary endpoints include functional decline, and the proportion of seniors with frailty, sarcopenia, and loss of autonomy. STRONG will further assess the cost-effectiveness of the interventions based on health care utilization data collected every 2 months from each participant and observed incidence of the endpoints. Mechanistic endpoints include change in muscle mass by DXA(arms and legs), change in myostatin levels, and muscle quality (based on MRI).

The interventions are (1) a simple home exercise program (a validated strength-enhancing or a control joint flexibility exercise program) to be performed 3x30 minutes/week; and (2) protein supplementation (either 20g of whey protein or isocaloric powder given in two portions for breakfast and dinner each day). All participants will receive a control dose of 24'000 IU vitamin D per month (equivalent to 800 IU vitamin D/day) to ensure that over 97% of STRONG participants will be vitamin D replete (25-hydroxyvitamin D \> 20 ng/ml) during the course of the trial.

The trial will have clinical visits at baseline, 6 months, and 12 months. In between clinical visits, telephone interviews will be performed every 2 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Frailty Malnutrition; Protein Fall

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

2x2 factorial design

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protein Supplement plus Active Exercise

Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)

Group Type ACTIVE_COMPARATOR

Protein Supplement

Intervention Type DIETARY_SUPPLEMENT

Predosed protein powder; can be added to various dishes and drinks

Active Exercise

Intervention Type PROCEDURE

Program includes five strength exercises that can be easily performed at home

Protein-free Supplement plus Active Exercise

Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)

Group Type ACTIVE_COMPARATOR

Protein-free Supplement

Intervention Type DIETARY_SUPPLEMENT

Predosed protein-free powder; can be added to various dishes and drinks

Active Exercise

Intervention Type PROCEDURE

Program includes five strength exercises that can be easily performed at home

Protein Supplement plus Control Exercise

Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)

Group Type ACTIVE_COMPARATOR

Protein Supplement

Intervention Type DIETARY_SUPPLEMENT

Predosed protein powder; can be added to various dishes and drinks

Control Exercise

Intervention Type PROCEDURE

Program includes five flexibility exercises that can be easily performed at home

Protein-free Supplement plus Control Exercise

Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)

Group Type SHAM_COMPARATOR

Protein-free Supplement

Intervention Type DIETARY_SUPPLEMENT

Predosed protein-free powder; can be added to various dishes and drinks

Control Exercise

Intervention Type PROCEDURE

Program includes five flexibility exercises that can be easily performed at home

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Protein Supplement

Predosed protein powder; can be added to various dishes and drinks

Intervention Type DIETARY_SUPPLEMENT

Protein-free Supplement

Predosed protein-free powder; can be added to various dishes and drinks

Intervention Type DIETARY_SUPPLEMENT

Active Exercise

Program includes five strength exercises that can be easily performed at home

Intervention Type PROCEDURE

Control Exercise

Program includes five flexibility exercises that can be easily performed at home

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Moltein® Ready-to-Shake

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 1 of 5 frailty criteria, definition by Linda Fried: 1) weight loss of \> 4.5 kg in the last 12 months; 2) reduced grip strength in Martin Vigorimeter test: ♂ ≤ 64 kPa, ♀ ≤ 42 kPa; 3) standardized question on exhaustion as published by Fried et al.; 4) gait speed \< 1 m/s; 5) 6-minute walk test \< 300 meters and/or Injurious (any injury) low trauma fall in the last 12 months prior to enrollment
* Reduced protein intake defined as a score ≤ 0.5 at item K of the Mini Nutritional Assessment (MNA)
* Community-dwelling or assisted living

Exclusion Criteria

* Mini-mental state examination (MMSE) \< 24 (inability to follow the study procedures and give written informed consent)
* Inability to come to the trial centers
* Inability to walk at least 3 meters with or without walking aid
* Severe kidney impairment (Glomerular filtration rate \[GFR\] \< 30 ml/min)
* Inability to follow exercise instruction or inability to take protein powder mixed in drink or food (test at baseline screening examination)
* Severe gait impairment or diseases with a risk of recurrent falling (due to conditions such as, e.g. Parkinson's disease/syndrome, Hemiplegia after stroke, symptomatic stenosis of the spinal canal, polyneuropathy, epilepsy, recurring vertigo, recurring syncope)
* Major visual or hearing impairment or other serious illness that would preclude participation (e.g. alcohol abuse, alcoholic disease)
* Inability to read/speak/write in German (necessary to follow instructions incl. STRONG exercise manual)
* Living in a nursing home
* Contraindication to treatment (e.g. allergy)
* Contraindication to the vitamin D standard of care therapy

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes